Background Gefitinib is active in patients with pretreated non-small-cell lung cancer
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …

Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer
(NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval …

The present network meta‑analysis aimed to compare the effectiveness and adverse effects
of gefitinib, erlotinib and icotinib in the treatment of patients with non‑small cell lung cancer …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs …

Gefitinib is an orally bioavailable, EGF receptor tyrosine kinase inhibitor and was the first
targeted drug to be approved for non-small-cell lung cancer (NSCLC). Identification of …

Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such
as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of …

Opinion statement Gefitinib is a small molecule that specifically inhibits the tyrosine kinase
activity of the epidermal growth factor receptor (EGFR) type 1 by interfering with the …